PracticeVideosBlogFlashcardsEspañol

Free exam prep

ANCC-AGPCNP-BC

Practice QuestionsStudy Guide

10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis

Key Takeaways

  • Rheumatoid Arthritis (RA) is an autoimmune systemic inflammatory disorder causing symmetric, destructive polyarthritis targeting small joints (MCP, PIP, MTP, wrists) with prolonged morning stiffness (>60 minutes); anti-cyclic citrullinated peptide (anti-CCP) antibodies provide >95% specificity and predict erosive disease.
  • Early initiation of disease-modifying antirheumatic drugs (DMARDs) within 3 months of RA diagnosis prevents irreversible joint destruction; Methotrexate is the gold-standard anchor csDMARD requiring folic acid supplementation (1 mg/day) and routine monitoring of CBC, liver enzymes, and renal function.
  • Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease diagnosed via the 2019 EULAR/ACR criteria requiring positive ANA (≥1:80) followed by weighted criteria; Hydroxychloroquine is the foundational life-prolonging therapy for all SLE patients, requiring baseline and annual retinal toxicity screening after 5 years.
  • Polymyalgia Rheumatica (PMR) presents in adults ≥50 with acute/subacute bilateral aching and morning stiffness in the shoulder and pelvic girdles, markedly elevated ESR/CRP, and normal muscle enzymes (CK); it exhibits a dramatic clinical response within 24–72 hours to low-dose prednisone (15–20 mg/day).
  • Giant Cell Arteritis (GCA) is a large-vessel vasculitis that represents an ophthalmic emergency; if temporal headache, jaw claudication, scalp tenderness, or visual symptoms occur, high-dose systemic corticosteroids (prednisone 40–60 mg/day or IV pulse methylprednisolone) must be initiated IMMEDIATELY without waiting for temporal artery biopsy results.
Last updated: August 2026

Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis

Autoimmune rheumatologic conditions represent complex, multisystem disorders driven by loss of immunological self-tolerance, chronic autoantibody production, and uncontrolled cytokine cascades. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), early disease detection, accurate serologic interpretation, aggressive initiation of disease-modifying therapies, and proactive surveillance for medication toxicity and life-threatening vascular complications are paramount board competencies.

1. Rheumatoid Arthritis (RA)

Pathophysiology & Immunopathogenesis

Rheumatoid arthritis is a chronic, systemic autoimmune inflammatory disease characterized by destructive synovitis. Genetic susceptibility (specifically the HLA-DRB1 "shared epitope") interacts with environmental triggers (such as tobacco smoking and periodontal disease) to stimulate the enzymatic conversion of arginine to citrulline (citrullination).

+---------------------------------------------------------------------------------------------------+
|                                 RHEUMATOID ARTHRITIS IMMUNOPATHOGENESIS                           |
|                                                                                                   |
|   Environmental Trigger (Smoking) + Genetic Susceptibility (HLA-DRB1 Shared Epitope)              |
|                                     |                                                             |
|                                     v                                                             |
|   Post-Translational Protein Citrullination -> Anti-CCP & RF Autoantibody Production              |
|                                     |                                                             |
|                                     v                                                             |
|   Synovial Microvascular Proliferation & Massive Infiltration (T cells, B cells, Macrophages)     |
|                                     |                                                             |
|                                     v                                                             |
|   Cytokine Hypersecretion (TNF-alpha, IL-1, IL-6, IL-17, RANKL)                                   |
|                                     |                                                             |
|                                     v                                                             |
|   INVASIVE SYNOVIAL PANNUS FORMATION (Hyperplastic synoviocytes + Osteoclasts + Chondrocytes)     |
|                                     |                                                             |
|                                     v                                                             |
|   Marginal Bone Erosions + Cartilage Degradation + Tendon Rupture + Systemic Vascular Inflammation|
+---------------------------------------------------------------------------------------------------+

Clinical Presentation & Deformity Patterns

  • Joint Manifestations:
    • Symmetric, polyarticular inflammatory arthritis affecting small joints of the hands and feet.
    • Primary Targets: Metacarpophalangeal (MCP) joints, Proximal Interphalangeal (PIP) joints, Wrists, Metatarsophalangeal (MTP) joints, Knees, Ankles, and Cervical Spine (specifically C1-C2 atlantoaxial articulation).
    • Characteristic Spares: RA characteristically SPARES the Distal Interphalangeal (DIP) joints and the thoracolumbar spine.
  • Symptom Chronometry: Prolonged morning stiffness lasting $>60\text{ minutes}$ (often 2–3 hours), which characteristically improves with physical movement, warm showers, and gentle exercise throughout the day.
  • Advanced Joint Deformities:
    • Swan-Neck Deformity: Hyperextension of PIP joint with compensatory flexion of DIP joint.
    • Boutonnière Deformity: Flexion of PIP joint with hyperextension of DIP joint (rupture of central extensor tendon slip).
    • Ulnar Drift (Deviation): Subluxation and lateral deviation of the fingers at the MCP joints.
    • Z-Deformity of the Thumb: Fixed flexion at MCP joint and hyperextension at IP joint.
    • Rheumatoid Nodules: Firm, non-tender, subcutaneous nodules located over pressure points (olecranon bursa, extensor forearm, Achilles tendon, and pulmonary parenchyma).
+---------------------------------------------------------------------------------------------------+
|                         EXTRA-ARTICULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS                    |
|                                                                                                   |
|   ORGAN SYSTEM       CLINICAL MANIFESTATION & PATHOLOGY                                           |
|   ---------------------------------------------------------------------------------------------   |
|   Ocular             Keratoconjunctivitis sicca (Secondary Sjögren syndrome, 15-20%), Episcleritis,|
|                      Scleritis (deep agonizing eye pain, risk of globe perforation: scleromalacia)|
|   Pulmonary          Rheumatoid Interstitial Lung Disease (ILD - UIP/NSIP patterns), Pleural      |
|                      effusions (exudative with characteristic VERY LOW GLUCOSE < 30 mg/dL),       |
|                      Caplan syndrome (RA + pneumoconiosis + pulmonary nodules)                    |
|   Cardiovascular     Accelerated Atherosclerosis (leading cause of mortality in RA!), Pericarditis|
|   Hematologic        Anemia of Chronic Disease (normocytic/microcytic), Thrombocytosis (acute     |
|                      phase marker), FELTY SYNDROME (Triad: Severe RA + Splenomegaly + Neutropenia)|
|   Neurologic         Cervical Spine Atlantoaxial Subluxation (C1-C2 instability with danger of    |
|                      quadriplegia/death during intubation!), Peripheral entrapment neuropathies   |
|   Vascular           Rheumatoid Vasculitis (palpable purpura, cutaneous ulcerations, mononeuritis)|
+---------------------------------------------------------------------------------------------------+

Diagnostic Serology, Synovial Fluid & Radiography

+---------------------------------------------------------------------------------------------------+
|                             DIAGNOSTIC SEROLOGY COMPARISON IN RA                                  |
|                                                                                                   |
|   SEROLOGIC MARKER            SENSITIVITY    SPECIFICITY    CLINICAL SIGNIFICANCE                 |
|   ---------------------------------------------------------------------------------------------   |
|   Anti-CCP (ACPA)             ~ 70 - 80%     > 95 - 98%     Highest specificity; appears years    |
|   (Anti-Cyclic Citrullinated                                before clinical onset; strong         |
|   Peptide Antibody)                                         predictor of aggressive erosive RA.   |
|                                                                                                   |
|   Rheumatoid Factor (RF)      ~ 70 - 80%     ~ 75 - 80%     IgM antibody directed against Fc      |
|   (IgM against IgG Fc)                                      portion of IgG. Also positive in:     |
|                                                             Sjögren, SLE, Hepatitis C, TB,       |
|                                                             Infective Endocarditis, Healthy aged. |
|                                                                                                   |
|   ESR & CRP                   ~ 80 - 90%     Non-specific   Correlates with active synovitis and  |
|                                                             systemic disease activity.            |
+---------------------------------------------------------------------------------------------------+
  • Synovial Fluid Analysis: Inflammatory profile: yellow/turbid fluid, leukocyte count $2,000\text{--}50,000/\mu\text{L}$ with $>50%$ polymorphonuclear leukocytes (PMNs), normal glucose-to-serum ratio, negative Gram stain, and no crystals.
  • Plain Radiography: Early findings reveal periarticular soft tissue swelling and periarticular osteopenia (demineralization); progressive disease demonstrates marginal bone erosions (at the joint capsule insertions where bone lacks protective cartilage) and uniform, symmetric joint space narrowing.
  • Pre-Operative Cervical Spine Mandate: Any patient with longstanding RA undergoing elective surgery requiring general endotracheal intubation MUST obtain flexion and extension cervical spine radiographs to rule out occult atlantoaxial subluxation (anterior atlantodental interval $>3\text{ mm}$) to prevent spinal cord transection during airway manipulation.

Stepwise Guideline-Directed Pharmacotherapy (ACR Guidelines)

Treat-to-Target (T2T) strategy aims for clinical remission or low disease activity. Disease-Modifying Antirheumatic Drugs (DMARDs) must be initiated immediately upon diagnosis (ideally within 3 months of symptom onset):

+---------------------------------------------------------------------------------------------------+
|                         STEPWISE PHARMACOTHERAPY ALGORITHM FOR RA                                 |
|                                                                                                   |
|   FIRST-LINE: CONVENTIONAL SYNTHETIC DMARD (csDMARD)                                              |
|   * METHOTREXATE (MTX) is the foundational anchor drug of choice (15-25 mg PO or SubQ ONCE WEEKLY)|
|     - Mechanism: Dihydrofolate reductase inhibitor; increases adenosine anti-inflammatory actions.|
|     - Mandatory Co-Prescription: FOLIC ACID 1 mg daily (reduces stomatitis, GI upset, cytopenias).|
|     - Monitoring: Baseline & every 8-12 weeks: CBC (myelosuppression), LFTs (hepatotoxicity),     |
|       Serum Creatinine (renally excreted; dose reduce/avoid if eGFR < 30 mL/min).                 |
|     - Absolute Contraindications: PREGNANCY (Teratogenic / Category X), severe hepatic cirrhosis, |
|       active heavy alcohol consumption, severe renal impairment.                                  |
|     - Toxicity Red Flag: Acute dry cough, fever, dyspnea -> Methotrexate-Induced Pneumonitis.     |
|   * Alternative / Combination csDMARDs:                                                           |
|     - Hydroxychloroquine (HCQ) 200-400 mg daily (mild disease; annual eye exams for retinopathy).  |
|     - Sulfasalazine 1-3 g daily (screen G6PD; causes orange discoloration of urine/tears).        |
|     - Leflunomide (pyrimidine synthesis inhibitor; long half-life, requires cholestyramine washout)|
|                                     |                                                             |
|                                     v (Moderate-to-High disease activity despite 3 months csDMARD)|
|   SECOND-LINE: BIOLOGIC DMARDs (bDMARDs) OR TARGETED SYNTHETIC DMARDs (tsDMARDs)                  |
|   * Anti-TNF Biologics (e.g., Adalimumab, Etanercept, Infliximab, Golimumab, Certolizumab):       |
|     - Pre-Treatment Screening MANDATE: Tuberculin Skin Test (TST) or QuantiFERON-TB Gold AND       |
|       Hepatitis B Serology (HBsAg, anti-HBc) to rule out latent infection reactivation.           |
|     - Black Box Warnings / Contraindications: Active severe infection, Demyelinating disease      |
|       (Multiple Sclerosis), NYHA Class III / IV Heart Failure (worsens congestive heart failure!). |
|   * Non-TNF Biologics:                                                                            |
|     - Rituximab (Anti-CD20 B-cell depleter; screen for Hepatitis B reactivation / PML).           |
|     - Abatacept (T-cell co-stimulation modulator / CTLA-4-Ig).                                    |
|     - Tocilizumab / Sarilumab (IL-6 receptor antagonists; monitor LFTs, lipids, diverticulitis).  |
|   * Targeted Synthetic DMARDs (JAK Inhibitors: Tofacitinib, Upadacitinib, Baricitinib):           |
|     - Oral small molecules; Black Box Warnings for Major Adverse Cardiovascular Events (MACE),    |
|       deep vein thrombosis / pulmonary embolism (VTE), malignancies, and serious infections.      |
|                                     |                                                             |
|                                     v (Bridge therapy only)                                       |
|   GLUCOCORTICOID BRIDGING                                                                         |
|   - Low-dose oral Prednisone (<= 10 mg/day) used strictly as short-term bridge therapy while       |
|     awaiting csDMARD onset of clinical efficacy (which requires 6 to 12 weeks). Taper promptly.   |
+---------------------------------------------------------------------------------------------------+

2. Systemic Lupus Erythematosus (SLE)

Pathophysiology & Diagnostic Criteria

SLE is a prototypical systemic autoimmune disease characterized by polyclonal B-cell hyperreactivity, defective clearance of apoptotic nuclear debris, production of antinuclear autoantibodies, and widespread tissue damage mediated by Type III (immune complex deposition) and Type II (autoantibody-mediated cytotoxicity) hypersensitivity reactions.

+---------------------------------------------------------------------------------------------------+
|                           2019 EULAR / ACR CRITERIA & THE "SOAP BRAIN MD" FRAMEWORK               |
|                                                                                                   |
|   ENTRY CRITERION: Antinuclear Antibodies (ANA) titer >= 1:80 on HEp-2 cells (Mandatory!)        |
|                                                                                                   |
|   * S - SEROSITIS (Pleuritis, Pericarditis / Pericardial effusion)                                |
|   * O - ORAL ULCERS (Painless oral or nasopharyngeal ulcerations, especially on hard palate)      |
|   * A - ARTHRITIS (Non-erosive, inflammatory polyarthritis involving >= 2 peripheral joints)      |
|   * P - PHOTOSENSITIVITY (Skin rash in unusual reaction to sunlight)                              |
|   * B - BLOOD CYTOPENIAS (Autoimmune hemolytic anemia, Leukopenia <4,000, Lymphopenia <1,000,     |
|         Thrombocytopenia <100,000/mcL in absence of other causes)                                 |
|   * R - RENAL DISORDER (Persistent proteinuria >0.5 g/24h or active cellular RBC casts)          |
|   * A - ANA POSITIVITY (Present in >99% of patients; high sensitivity, low specificity)           |
|   * I - IMMUNOLOGIC MARKERS (Anti-dsDNA, Anti-Smith [Anti-Sm], Antiphospholipid Antibodies)       |
|   * N - NEUROLOGIC DISORDERS (Seizures, Psychosis, Acute confusional state, Mononeuritis)         |
|   * M - MALAR (BUTTERFLY) RASH (Fixed erythema over malar eminences, SPARING NASOLABIAL FOLDS)    |
|   * D - DISCOID RASH (Erythematous raised patches with keratotic scaling, causing atrophic scars) |
+---------------------------------------------------------------------------------------------------+

Serologic Autoantibody Profile in SLE

Serologic TestSensitivitySpecificityClinical Utility & Pearls
Antinuclear Antibody (ANA)$>99%$Low (~60%)Best initial screening test. High negative predictive value; if ANA is negative, SLE is virtually excluded.
Anti-dsDNA (Double-stranded DNA)~60–70%$>95%$Highly specific. Titers fluctuate directly with disease activity; elevated titers correlate with active Lupus Nephritis.
Anti-Smith (Anti-Sm)~25–30%$>99%$Most specific autoantibody for SLE. Does NOT fluctuate with disease activity.
Anti-Ro (SSA) / Anti-La (SSB)~30–40%ModerateAssociated with subacute cutaneous lupus, secondary Sjögren syndrome, and Neonatal Lupus / Congenital Heart Block in offspring.
Complement (C3 and C4)VariableVariableDecreased / consumed (low C3/C4) during acute immune-complex mediated disease flares and active nephritis.
Antiphospholipid Antibodies~30–40%ModerateLupus Anticoagulant, Anticardiolipin IgG/IgM, Anti-$\beta_2$-glycoprotein I. Triggers arterial/venous thrombosis and recurrent pregnancy loss. Paradoxically causes prolonged PTT in vitro!

Drug-Induced Lupus Erythematosus (DILE)

  • Common Culprit Medications: Hydralazine, Procainamide, Isoniazid (INH), Minocycline, Quinidine, and anti-TNF biologics.
  • Diagnostic Serologic Hallmark: Anti-Histone Antibodies are positive in $>95%$ of cases.
  • Clinical Distinction from Idiopathic SLE: DILE characteristically SPARES the kidneys and central nervous system, Anti-dsDNA and Anti-Sm are typically negative, and complement levels are normal. Symptoms spontaneously resolve within weeks to months following discontinuation of the culprit drug.

Guideline-Directed SLE Management

  1. Hydroxychloroquine (HCQ / Plaquenil): Strongly recommended as universal foundational therapy for ALL patients with SLE regardless of disease severity. HCQ reduces flare rates, prevents organ damage accrual, decreases thrombotic events, and reduces overall mortality. Dosed $\le 5\text{ mg/kg actual body weight/day}$ to minimize retinal toxicity. Mandatory baseline and annual dilated ophthalmologic examinations after 5 years of therapy to screen for irreversible bull's-eye retinopathy.
  2. Systemic Corticosteroids: Used for acute disease flares; high-dose pulse IV Methylprednisolone ($1,000\text{ mg/day x 3 days}$) for organ-threatening complications (e.g., diffuse proliferative lupus nephritis, acute neuropsychiatric lupus).
  3. Immunosuppressive Agents for Lupus Nephritis: Mycophenolate Mofetil (MMF) or IV Cyclophosphamide followed by maintenance MMF or Azathioprine; Belimumab (B-lymphocyte stimulator inhibitor) or Voclosporin as add-on therapy.

3. Polymyalgia Rheumatica (PMR) & Giant Cell Arteritis (GCA)

Polymyalgia Rheumatica and Giant Cell Arteritis represent distinct clinical manifestations along the same inflammatory disease continuum in older adults ($15\text{--}20%$ of PMR patients develop GCA; up to $50%$ of GCA patients exhibit PMR features).

+---------------------------------------------------------------------------------------------------+
|                         PMR vs. GCA DIAGNOSTIC & CLINICAL COMPARISON                              |
|                                                                                                   |
|   CLINICAL FEATURE            POLYMYALGIA RHEUMATICA (PMR)       GIANT CELL ARTERITIS (GCA)       |
|   ---------------------------------------------------------------------------------------------   |
|   Target Population           Age >= 50 years (Mean age 73)      Age >= 50 years (Mean age 75)    |
|   Anatomical Localization     Synovial / Bursal structures of    Medium & large elastic arteries  |
|                               proximal shoulder & pelvic girdles (Temporal, ophthalmic, aorta)    |
|   Hallmark Symptoms           Bilateral aching & severe morning  New-onset unilateral headache,   |
|                               stiffness in neck, shoulders, hips; jaw claudication, scalp         |
|                               difficulty rising from chair.      tenderness, amaurosis fugax.     |
|   Physical Examination        Active ROM limited by pain;        Tender, nodular, pulseless       |
|                               muscle strength is NORMAL.         temporal artery; visual defect.  |
|   Erythrocyte Sed. Rate (ESR) Markedly Elevated (often > 50-100) Markedly Elevated (often > 100)  |
|   Creatine Kinase (CK)        NORMAL (Rules out myositis/statin) NORMAL                           |
|   Gold Standard Diagnostic    Clinical diagnosis + rapid         TEMPORAL ARTERY BIOPSY (TAB)     |
|                               response to low-dose steroids.     (>= 1-2 cm specimen, skip lesions)|
|   First-Line Therapy          Low-Dose Oral Prednisone           HIGH-DOSE SYSTEMIC STEROIDS      |
|                               (15 - 20 mg daily).                (Prednisone 40-60 mg PO daily;   |
|                                                                  IV Methylprednisolone 1 g daily  |
|                                                                  if visual loss threatened!).     |
|   Primary Complication        Chronic steroid adverse effects    IRREVERSIBLE BLINDNESS (AION)    |
+---------------------------------------------------------------------------------------------------+

Polymyalgia Rheumatica (PMR)

  • Clinical Presentation: Rapid or subacute onset of bilateral, symmetric aching pain and debilitating morning stiffness ($>45\text{--}60\text{ minutes}$) involving the proximal shoulder girdle (neck, deltoids), pelvic girdle (hips, buttocks), and upper thighs. Patients describe profound difficulty raising their arms to comb hair, reaching into high cabinets, putting on a coat, or standing up from a low seated position.
  • Diagnostic Confirmation: Markedly elevated ESR ($>50\text{ mm/hr}$) and CRP; normal muscle enzymes (Creatine Kinase is strictly normal, ruling out polymyositis, dermatomyositis, and statin-induced myopathy); negative RF and anti-CCP. Dramatic clinical improvement within 24 to 72 hours of initiating low-dose oral prednisone (15–20 mg/day) confirms the presumptive diagnosis. Steroids are gradually tapered over 1 to 2 years.

Giant Cell Arteritis (GCA / Temporal Arteritis) — Medical Emergency

  • Pathophysiology: Granulomatous vasculitis involving the medium and large arteries branching from the carotid system, especially the superficial temporal, ophthalmic, and posterior ciliary arteries.
  • Clinical Red Flags:
    • New-onset headache: Typically localized to the temporal or occipital region.
    • Jaw Claudication: Agonizing fatigue/cramping of the masseter muscles during mastication (pathognomonic sign of vascular ischemia!).
    • Scalp Tenderness: Pain elicited by brushing hair or resting head on a pillow.
    • Temporal Artery Changes: Palpable, tender, thickened, nodular, or pulseless temporal artery.
    • Visual Symptoms: Transient monocular vision loss (Amaurosis Fugax), diplopia, or sudden, painless, irreversible blindness secondary to Anterior Ischemic Optic Neuropathy (AION).
  • Urgent Action Protocol:
+---------------------------------------------------------------------------------------------------+
|                         EMERGENT GCA CLINICAL MANAGEMENT PROTOCOL                                 |
|                                                                                                   |
|   1. HIGH CLINICAL SUSPICION (New headache + Jaw claudication + ESR > 50-100 mm/hr)               |
|                                     |                                                             |
|                                     v                                                             |
|   2. IMMEDIATELY INITIATE HIGH-DOSE SYSTEMIC CORTICOSTEROIDS                                      |
|      - Uncomplicated GCA (No visual loss): PREDNISONE 40 - 60 mg PO DAILY.                        |
|      - Ocular Involvement (Amaurosis fugax, acute vision loss): IV METHYLPREDNISOLONE             |
|        1,000 mg IV DAILY for 3 days, followed by high-dose oral prednisone.                       |
|      * CRITICAL BOARD RULE: NEVER DELAY STEROID THERAPY TO AWAIT TEMPORAL ARTERY BIOPSY!         |
|                                     |                                                             |
|                                     v                                                             |
|   3. SCHEDULE TEMPORAL ARTERY BIOPSY (TAB) OR VASCULAR ULTRASOUND                                 |
|      - Obtain a long segment biopsy (>= 1.5-2.0 cm) to avoid missing segmental "skip lesions."    |
|      - Biopsy remains histopathologically positive for up to 1 to 2 weeks after steroid initiation.|
|      - Color Doppler Ultrasound may show the "halo sign" (hypoechoic vessel wall edema).          |
+---------------------------------------------------------------------------------------------------+

4. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Rheumatoid Arthritis: Morning stiffness >60 minutes, symmetric, targets MCP/PIP/wrist,        |
|     SPARES DIP! Anti-CCP is >95% specific. Start Methotrexate early + co-prescribe Folic Acid.   |
|                                                                                                   |
|   - Before starting TNF-inhibitors (Adalimumab, Etanercept): MANDATORY screening for Latent TB    |
|     (QuantiFERON) and Hepatitis B. Absolutely contraindicated in severe CHF (NYHA III/IV) and MS! |
|                                                                                                   |
|   - SLE Serology: ANA = Best initial screen (>99% sensitive). Anti-dsDNA = Correlates with        |
|     Lupus Nephritis flares and consumes complement (low C3/C4). Anti-Smith = Most specific.       |
|     Drug-induced lupus (Hydralazine, INH, Procainamide) = Anti-Histone positive.                  |
|                                                                                                   |
|   - Polymyalgia Rheumatica vs. Polymyositis: PMR has bilateral shoulder/pelvic morning stiffness, |
|     ESR >50, but NORMAL Creatine Kinase (CK) and normal strength. Responds instantly to low-dose  |
|     prednisone (15-20 mg). Polymyositis has TRUE proximal muscle weakness and elevated CK!        |
|                                                                                                   |
|   - Giant Cell Arteritis: Elderly patient with temporal headache, jaw claudication, and visual   |
|     changes. DO NOT wait for biopsy—start high-dose steroids (Prednisone 60 mg) IMMEDIATELY to     |
|     prevent irreversible ischemic blindness!                                                      |
+---------------------------------------------------------------------------------------------------+
Test Your Knowledge

A 36-year-old female presents to the primary care clinic with a 4-month history of fatigue, low-grade fevers, and progressively worsening pain and swelling in both hands and wrists. She reports that her hands feel stiff and immobile for approximately 2 hours every morning after waking, improving only after taking a hot shower and moving around. Physical examination reveals warm, spongy, boggy swelling and tenderness over the 2nd and 3rd metacarpophalangeal (MCP) joints and proximal interphalangeal (PIP) joints bilaterally, as well as bilateral wrist effusion. The distal interphalangeal (DIP) joints are completely unaffected. Laboratory studies reveal: ESR 58 mm/hr, CRP 24 mg/L, negative ANA, positive Rheumatoid Factor (RF) at 84 IU/mL, and positive Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibody at >250 U/mL. Bilateral hand radiographs show periarticular osteopenia and marginal cortical erosions at the 2nd MCP joint. What is the AGPCNP's most appropriate definitive disease-modifying treatment strategy?

A
B
C
D
Test Your Knowledge

A 74-year-old female presents with a 2-week history of a severe, throbbing right-sided temporal headache, mild low-grade fever, and profound fatigue. She reports that while chewing solid foods such as toast and meat, she experiences agonizing pain and cramping in her jaw muscles that forces her to stop eating. For the past 24 hours, she has noticed two brief episodes of painless, temporary vision loss in her right eye that resolved spontaneously after a few minutes ('like a curtain coming down'). On physical examination, the right superficial temporal artery is thickened, tender to palpation, and has a diminished pulse. Visual acuity is 20/25 OD and 20/20 OS. Point-of-care laboratory evaluation demonstrates an ESR of 98 mm/hr and CRP of 42 mg/L. What is the AGPCNP's immediate management priority?

A
B
C
D
Test Your Knowledge

A 28-year-old female presents to the clinic with persistent joint pain, fatigue, and a facial rash that worsens significantly following sun exposure. Physical examination reveals an erythematous, confluent macular rash across her cheeks and the bridge of her nose, with prominent sparing of the nasolabial folds. Laboratory testing reveals: ANA positive at 1:640 titer with a homogeneous pattern, Anti-dsDNA positive, Anti-Smith (Anti-Sm) positive, serum C3 48 mg/dL (low), and serum C4 8 mg/dL (low). Urinalysis demonstrates 3+ protein (2.2 g/24h) and 15–20 dysmorphic RBCs per high-power field with granular casts. She is not taking any medications. What is the most appropriate foundational pharmacologic agent that should be prescribed for this patient, and what monitoring is required?

A
B
C
D
Up Next

10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

Continue learning